Welcome! Login | Register
 

Giorgio: Ireland Leads the Way—Who would have thought that the tiny country…

NEW: CVS Charity Classic Adds Four to Field—CVS Charity Classic Adds Four to Field

NEW: MA Gas Prices Rise Three Cents—Gas prices in Massachusetts have gone up three…

Personal Tech For Women: 5 Things to Know About New, Smarter Food Label—Some of us might spend more time at…

Horowitz: Don’t Count Martin O’Malley Out—With all signals pointing to Martin O’Malley formally…

Organize + Energize: Be Prepared. Organize a First-Aid Kit—Organize + Energize: Be Prepared. Organize a First-Aid…

Angiulo: Unringing the Bell of Falsified Drug Tests—The concept of due process in criminal proceedings…

Revs, D.C. United Play to 1-1 Draw at Gillette—The New England Revolution (5-3-5) and the (6-2-4)…

Monfredo: Year 10 Engaging Readers in Worcester - Book Drive a Huge Success—The ability to read well is the single…

Fit for Life – Yes, You Can!—I was at a networking event last week…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.